Location · Ladson, SC
Clinical trials in Ladson, SC
8 recruiting studies have a site in Ladson, and 0 of them accept healthy volunteers.
8 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular…
AbbVie
- Location
- Ladson, SC + 54 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)
Merck Sharp & Dohme LLC
- Location
- Ladson, SC + 18 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1/Phase 2
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Sanofi
- Location
- Ladson, SC + 30 other US sites
- Eligibility basics
- Ages 60+
- RecruitingPhase 3
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
Amgen
- Location
- Ladson, SC + 54 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
Adverum Biotechnologies, Inc.
- Location
- Ladson, SC + 78 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO
Kodiak Sciences Inc
- Location
- Ladson, SC + 8 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2/Phase 3
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
EyeBiotech Ltd.
- Location
- Ladson, SC + 51 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 2
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in…
Apellis Pharmaceuticals, Inc.
- Location
- Ladson, SC + 77 other US sites
- Eligibility basics
- Ages 60+